Late-Breaking EADV 2026 Data Back DecisionDx-Melanoma Use in Melanoma
Late-breaking EADV 2026 data were framed as supporting DecisionDx-Melanoma use in sentinel lymph node biopsy decisions and risk-aligned post-surgical management of melanoma patients.